Inmates with hepatitis C sue Tennessee prison officials for treatment

See Costs: High cost of new HCV drugs strains prison budgets
July 2016 Tennessee:

Tennessee inmates infected with hepatitis C filed a federal lawsuit against state prison officials late Monday, asking the court to force the state to start treating all inmates who have the potentially deadly disease.

The lawsuit, filed by attorneys with the American Civil Liberties Union and other advocates in U.S. District Court in Nashville, says the Tennessee Department of Correction officials knowingly denying inmates care for their hepatitis C, also known as HCV, constitutes cruel and unusual punishment. It alleges the department is denying care because the best available medication is too expensive.



"In reality, (department officials) ignore the medical needs of (inmates) and class members in order to save costs. (The department's) written policies for HCV diagnosis, assessment and treatment utilize outdated standards of care and normalize the practice of refusing treatment for unjust and medically unsound reasons," the lawsuit states.

Prisoners Unlikely to Benefit from New, Highly Effective Hepatitis C Treatment

10-15-2014 National:

Hepatitis C (HCV) is a blood-borne virus that is typically spread through intravenous drug use (i.e., sharing needles), tattooing with non-sterile needles, and sharing razors, toothbrushes, nail clippers or other hygiene items that may be exposed to blood. It is often a chronic disease and, if left untreated, can lead to severe liver damage.

Recent good news in the battle against HCV, in the form of two new drugs that are highly effective in eliminating the virus, is tempered by the fact that the companies that produce the drugs have priced them at $60,000 to $80,000 per 12-week course of treatment. This high cost prices the medications beyond the reach of most prison and jail systems – which is especially troubling considering that a substantial number of prisoners are infected with HCV.

The new drugs, approved by the FDA in late 2013, are simeprevir, branded as Olysio and manufactured by Janssen Therapeutics (a Johnson & Johnson company), and sofosbuvir, branded as Sovaldi and manufactured by Gilead Sciences. Based on clinical trials, Sovaldi has an 84-96% cure rate while Olysio has an 80-85% cure rate. Both drugs are used in combination with other HCV anti-viral medications, peginterferon alfa and/or ribavirin, and their cure rates vary depending on HCV genotype – specific variations of the virus.